Dignitana AB is a Swedish medical technology company listed on the NASDAQ OMX First North stock exchange in Stockholm. The company is currently focusing on a widespread market launch of the DigniCap® scalp cooling system – a product that counteracts chemotherapy-related hair loss in breast cancer patients and may significantly contribute to improving patient well being and quality of life.

Dignitana develops a patented scalp cooling system, DigniCap®, that reduces chemotherapy-induced hair loss. Dignitana’s patented DigniCap® system has proven its safety and efficacy in clinical studies.

Dignitana, Inc. is a wholly owned subsidiary of Dignitana AB and is responsible for North American distribution and support for the DigniCap® scalp cooling system.

About the DigniCap® scalp cooling system. Dignitana’s core product – DigniCap® – is a patented scalp cooling system that offers women with breast cancer the ability to keep their hair during chemotherapy. DigniCap® provides continuous cooling with high efficacy, safety and acceptable patient comfort.

Information for

Learn about reducing hair loss for yourself or a loved one. Hear patients tell their stories about scalp cooling.

Find out when the DigniCap® scalp cooling system will be available near you.





Information for
Healthcare Professionals

Find out how scalp cooling can help your patients. Read about the science behind scalp cooling and clinical research findings on safety and efficacy.


Learn about

Find out where the DigniCap® scalp cooling system is currently available.